Hair loss

Celluma Light Therapy Introduces the RESTORE Hair Therapy System

Retrieved on: 
Thursday, March 14, 2024
DHT, Vitamin, Adenosine triphosphate, Serum, Inflammation, Zinc, Hair loss, Glycine, Scalp, ATP, FDA, Microcirculation, Peptide, Cosmetics

TUSTIN, Calif., March 14, 2024 /PRNewswire/ -- BioPhotas, Inc., the makers of Celluma Light Therapy and market leader in therapeutic LED light therapy devices, announced today the launch of the RESTORE Hair Serum, an optimized scalp and hair formulation that complements the award-winning Celluma RESTORE LED device to provide a complete hair-restoration solution.

Key Points: 
  • TUSTIN, Calif., March 14, 2024 /PRNewswire/ -- BioPhotas, Inc., the makers of Celluma Light Therapy and market leader in therapeutic LED light therapy devices, announced today the launch of the RESTORE Hair Serum, an optimized scalp and hair formulation that complements the award-winning Celluma RESTORE LED device to provide a complete hair-restoration solution.
  • "It's an amazingly elegant formulation that is clear and easily absorbed into the scalp so that it can be used daily to maximize the Celluma Light Therapy results."
  • For the growing number of professionals and individuals achieving significant and visible results with the FDA-cleared Celluma RESTORE Light Therapy device for hair restoration, this serum is an ideal complement for use between each light therapy treatment.
  • According to Mr. Cluff, "the Celluma RESTORE light therapy device has been available since receiving FDA-clearance for hair restoration in 2021.

Give Your Wash Day Experience a Brand-New Feel! Haircare Brand African Pride Introduces a Sensory Regimen with Its Newest Collection, Feel It Formula!

Retrieved on: 
Tuesday, March 12, 2024
Mineral oil, Sage oil, Target, Sulfate, Petroleum, Hair loss, Formula, Walmart, Peppermint, Rosemary, Scalp, SRP, Collection, Cosmetics

ATLANTA, March 12, 2024 /PRNewswire/ -- African Pride, the trusted and legacy haircare brand, proudly unveils its latest innovation – the 'Feel It Formula' haircare line. This 4-step collection is meticulously crafted to redefine the 'Wash Day Experience,' offering a sensory regimen that caters to all hair types, chemical, relaxed, or transitioning; restoring dry, damaged hair, and treating irritated scalps #feelthedifference.

Key Points: 
  • This 4-step collection is meticulously crafted to redefine the 'Wash Day Experience,' offering a sensory regimen that caters to all hair types, chemical, relaxed, or transitioning; restoring dry, damaged hair, and treating irritated scalps #feelthedifference.
  • The NEW African Pride 'Feel It Formula' line ignites your senses through stimulating fragrances, invigorating sensations, and nourishing formulas.
  • African Pride Feel It Formula Peppermint, Rosemary & Sage Strengthening Shampoo (SRP $6.99) - Deeply cleanses hair and scalp, removing product build-up without stripping moisture.
  • African Pride Feel It Formula Peppermint, Rosemary & Sage Strengthening Mask (SRP $6.99) - Strengthens and hydrates hair strands from root to tip.

ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars

Retrieved on: 
Tuesday, February 27, 2024
NSCLC, Therapy, Reflection nebula, Ophthalmology, Marketing, Investigational New Drug, Immune system, Myelodysplastic syndrome, Immunotherapy, Collateral damage, Shogun, FDA, Dietary supplement, US FDA, Polysaccharide, Nausea, Grifola frondosa, Hair loss, CDMO, Safety, MDS, Fatigue, CNS, TNBC, Edible, Ergosterol, Patient, Quality of life, Drug, Immunity, IND, Cancer

The Investigational New Drug (IND) application proposed the clinical investigation of BLEX 404 as the primary active ingredient.

Key Points: 
  • The Investigational New Drug (IND) application proposed the clinical investigation of BLEX 404 as the primary active ingredient.
  • The global cancer therapeutics market is expected to be worth around US$ 393.61 billion by 2032 from US$ 164 billion in 2022, growing at a CAGR of 9.20% from 2023 to 2032.
  • [4] Straits Research reports that the global botanical drug market size was valued at $163 million in 2021 and is expected to be valued at $3.2 billion.
  • The market is expected to grow at a CAGR of 39% during the forecast period (2022–2030).

Stemson Therapeutics and Bosley Parent Company, Aderans, Sign Exclusive Hair Regeneration Licensing Deal

Retrieved on: 
Saturday, March 9, 2024
Health, Consumer, Genetics, Other Health, General Health, Men, Anxiety, Woman, Hair loss, Quality of life, Tissue engineering, Cell, Medicine, IPSC, Therapy, Patient, Research, Depression, Pharmaceutical industry

Stemson Therapeutics and Aderans Company , the parent company of Bosley ® and HAIRCLUB ®, today announced an agreement securing Stemson the exclusive global rights to research, develop and commercialize hair regeneration therapeutic products based on Aderans’ proprietary hair regeneration cell therapy technology.

Key Points: 
  • Stemson Therapeutics and Aderans Company , the parent company of Bosley ® and HAIRCLUB ®, today announced an agreement securing Stemson the exclusive global rights to research, develop and commercialize hair regeneration therapeutic products based on Aderans’ proprietary hair regeneration cell therapy technology.
  • Stemson will resume Aderans’ Phase 2 clinical stage cell therapy hair regeneration program, integrate the technology into its existing hair loss cell therapy development pipeline, and provide multiple products for patients experiencing hair loss.
  • Aderans’ proprietary hair regeneration platform is a cell therapy system that utilizes patient-derived hair and skin cells to durably rejuvenate shrinking hair follicles in patients with Androgenetic Alopecia by repopulating functional hair follicle cells into early-to-mid stage hair loss areas.
  • “Aderans’ early pioneering work in cell therapy for hair loss demonstrated to the field the potential for durable long lasting hair regeneration results by restoring functional hair cells and tissue.

“One of the Biggest Innovations in Hair Loss We’ve Seen in Twenty-Five Years” -- BosleyMD® Teams With Start-up Yuva Biosciences in National Launch of Breakthrough Technology

Retrieved on: 
Tuesday, February 20, 2024
Technology, Professional Services, Health, Marketing, Biometrics, Communications, Other Technology, Cosmetics, Retail, Data Analytics, Artificial Intelligence, Foam, Hospital, Procter, Senior, Woman, Research, Entrepreneurship, Multimedia, Artificial intelligence, Hair loss, Mitochondrion, News, Ageing, Human, MIT, Y100, Harvard University, Skin, Oil, Fertility, Crest, Skin care, University, Translation, Organization, P&G, Science, Longevity, Crest Whitestrips, Procter & Gamble, McKinsey & Company, Dietary supplement

BosleyMD® is rolling out its new Revive Plus Densifying Foam with YuvaBio® Y100™ technology for men and women to major national mass retailers, beauty chains, pharmacy chains, and e-commerce sites.

Key Points: 
  • BosleyMD® is rolling out its new Revive Plus Densifying Foam with YuvaBio® Y100™ technology for men and women to major national mass retailers, beauty chains, pharmacy chains, and e-commerce sites.
  • Critical pioneering science in mitochondrial science has been driven by Dr. Keshav K. Singh, Chief Scientific Officer and Co-Founder of Yuva Biosciences.
  • Yuva Biosciences experts used AI to identify molecules that could restore mitochondrial function, of which Y100 is the first to market out of the pipeline.
  • "Yuva Biosciences' technology solves this problem with once-in-a-generation innovation by fighting a key root cause of aging, mitochondrial dysfunction.

Pelage Presents Late-Breaking Data at AAD 2024 Meeting Demonstrating PP405 Activates Human Hair Follicle Stem Cells Ex Vivo and in Phase 1 Clinical Study

Retrieved on: 
Saturday, March 9, 2024
MPC, Woman, LDH, CMO, LOS, Hair loss, Blood, Pattern hair loss, Biopsy, Fur, Skin, Data, Annual general meeting, B cell, AAD, Patient, Clinical trial, Inhibitor, American Academy, Pharmaceutical industry

LOS ANGELES, March 9, 2024 /PRNewswire/ -- Pelage Pharmaceuticals, a clinical-stage regenerative medicine company pioneering a new generation of treatments for hair loss, today presented positive translational and Phase 1 clinical data demonstrating the company's novel small molecule therapy PP405 reactivates dormant hair follicle stem cells to trigger hair growth. Data were presented in a late-breaking oral session of the American Academy of Dermatology (AAD) 2024 Annual Meeting in San Diego, titled Inhibition of pyruvate oxidation activates human hair follicle stem cells ex vivo.

Key Points: 
  • Data were presented in a late-breaking oral session of the American Academy of Dermatology (AAD) 2024 Annual Meeting in San Diego, titled Inhibition of pyruvate oxidation activates human hair follicle stem cells ex vivo.
  • "The translational data derived from our ex vivo studies on human facelift skin have been further validated in a Phase 1 first-in-human clinical trial demonstrating PP405 effectively reactivates dormant hair follicle stem cells," said Daniel Gil, Ph.D., CEO of Pelage Pharmaceuticals.
  • The LDH activity corresponded with a significant increase in Ki67 signal in the hair bulge, indicating a proliferative response of the hair follicle stem cells.
  • PP405 may also have applications for other forms of alopecia, including telogen effluvium (stress-induced hair loss) and chemotherapy-induced hair loss.

Patient-Reported Outcomes Data from Longest Running Dermatology Study: TARGET-DERM AA Poster Presented at American Academy of Dermatology (AAD) 2024

Retrieved on: 
Friday, March 8, 2024
Alopecia areata, Anxiety, Natural history, Psoriasis, Autoimmune disease, Professor, Assistant, Hair loss, Quality of life, Atopic dermatitis, Alopecia totalis, Skin, Mental, Entrepreneurship, RWE, Hashimoto's thyroiditis, AA, AAD, Vitiligo, University, Hidradenitis suppurativa, Patient, Disease, Dermatitis, Diagnosis, Social stigma, Depression, Nursing

DURHAM, N.C., March 8, 2024 /PRNewswire/ -- New patient-reported outcomes data presented at AAD 2024 from Target RWE's TARGET-DERM AA registry confirms the high unmet need and significant disease burden in patients with moderate to severe alopecia areata (AA). TARGET-DERM is the largest and most comprehensive longitudinal RWE study observing patients with immune-mediated inflammatory skin conditions in the United States.

Key Points: 
  • Patients with AA have a high unmet medical need due to comorbid conditions and high impact on quality of life.
  • The most common comorbid conditions associated with AA include vitiligo, atopic dermatitis (eczema), Hashimoto's thyroiditis, psoriasis, and systemic lupus erythematosus.
  • TARGET-DERM AA is distinctively positioned to address real-world access to care, disease progression, diagnosis, and treatment in patients with moderate to severe AA.
  • "What's important about our data presented at AAD and TARGET-DERM AA is that we are gaining insights on the impact of the disease.

CurlDaze Launches New GroDAZE Collection Exclusively at Wal-Mart

Retrieved on: 
Monday, March 4, 2024
Collection, Hair loss, Caffeine, Walmart, Growth, Seed, Health, Scalp, Castor oil, Massage, Research, Beauty, Cosmetics

LOS ANGELES, March 4, 2024 /PRNewswire/ -- It's a significant leap forward in haircare innovation. CurlDaze, one of the most dynamic Black-owned and women-driven beauty brands, that has gone viral on Tik-Tok, proudly unveils the GroDAZE Collection, a unique range tailored for curly, coily, and wavy hair enthusiasts. Rooted in the rich traditions of Fenugreek and further energized by potent ingredients such as castor oil and caffeine, this exclusive Wal-Mart collection redefines scalp and hair health.

Key Points: 
  • CurlDaze, one of the most dynamic Black-owned and women-driven beauty brands, that has gone viral on Tik-Tok, proudly unveils the GroDAZE Collection, a unique range tailored for curly, coily, and wavy hair enthusiasts.
  • Now, CurlDaze seamlessly integrates this leafy green herb, brimming with protein, plant compounds, and nicotinic acid, to address hair loss and invigorate hair growth.
  • Robyn Atwater, the genius behind the brand that went viral on Tik Tok, CurlDaze, shares, "GroDAZE isn't just a collection; it's the embodiment of countless days of research, understanding, and passion.
  • Exclusively at Wal-Mart, today, March 4th, this groundbreaking collection will be gracing the aisles of Wal-Mart stores, ensuring that wherever you are, is accessible to you.

Trixie Mattel to Host The Podcast Academy's Fourth Annual Awards for Excellence In Audio; Malcolm Gladwell and Ira Madison III to be Honored at March 26 Ceremony in LA

Retrieved on: 
Monday, March 4, 2024
Television, Pushkin Industries, LOS, MTV News, Vulture, Trixie Motel, Jimmy Kimmel Live!, NPR, RuPaul, Ambies, Livestreaming, Top Heatseekers, TPA, Crooked Media, Hair loss, UNHhhh, I Like to Watch, Broken Record, Performing arts of Australia, Random House, RuPaul's Drag Race, The Bomber Mafia, JW Marriott Hotels, LP, News, The Tipping Point, Ceremony, Tipping point, Q-Force, Politics, Paris Wells, Revisionist history, Billboard, Community, Beautiful, Trixie Mattel, Daybreak, Stagecoach Festival, Entertainment

LOS ANGELES, March 4, 2024 /PRNewswire-PRWeb/ -- The Podcast Academy, the preeminent professional podcast organization, announced today that season 3 winner of "RuPaul's Drag Race All Stars" Trixie Mattel will host its fourth annual Awards for Excellence in Audio (The Ambies) on March 26 at the JW Marriott LA Live Los Angeles. TPA also unveiled that it will bestow upon Malcolm Gladwell the esteemed Governors Award, which recognizes a podcast or individual for the compelling influence they've had on the industry. Additionally, TPA will honor pop-culture podcaster, Ira Madison III with the Impact Award, which recognizes an individual or podcast that has made a significant, positive effect on its listeners. The ceremony will be livestreamed at TPA's YouTube Channel beginning at 6:00p.m. PT.

Key Points: 
  • Trixie Mattel to Host The Podcast Academy's Fourth Annual Awards for Excellence In Audio; Malcolm Gladwell to be Honored with the Governors Award; Ira Madison III to Receive Impact Award on March 26 in LA; The Ambies will be Livestreamed at TPA's YouTube Channel Beginning at 6:00p.m.
  • Additionally, TPA will honor pop-culture podcaster, Ira Madison III with the Impact Award, which recognizes an individual or podcast that has made a significant, positive effect on its listeners.
  • The ceremony will highlight 192 nominees across 27 categories with winners to be selected by every voting member of The Podcast Academy (TPA).
  • Ira Madison III is a cultural critic, TV writer, and host of the Crooked Media award-winning podcast "Keep It."

Celluma Light Therapy Announces Launch of Revolutionary Body Contouring Device

Retrieved on: 
Friday, March 1, 2024
XL, Acne, Lipid, Diet, Hair loss, FDA, Oil lamp, Ageing, Skin, Pain management, Adipocyte, Elective surgery, Adipose tissue, LLLT, Observational study, LED

TUSTIN, Calif., March 1, 2024 /PRNewswire/ -- BioPhotas, Inc., the market leader in therapeutic LED Light Therapy Devices, announced today the launch of the Celluma CONTOUR, the only FDA-cleared light therapy device treating body contouring, aging skin, and pain management.

Key Points: 
  • TUSTIN, Calif., March 1, 2024 /PRNewswire/ -- BioPhotas, Inc., the market leader in therapeutic LED Light Therapy Devices, announced today the launch of the Celluma CONTOUR, the only FDA-cleared light therapy device treating body contouring, aging skin, and pain management.
  • "The Celluma CONTOUR is the first LED Light Therapy device to be FDA-cleared on an Over-The-Counter basis for body contouring," commented BioPhotas President and CEO, Curtis Cluff.
  • "It is also the only LED light therapy device on the market designed with multiple treatment modes for reducing wrinkles, reducing muscle and joint pain, as well as body contouring in a single device."
  • Low Level Light Therapy (LLLT) for body contouring is a proven, non-invasive technique to reduce the circumference of the hips, waist, and thighs safely and effectively.